Navigation Links
Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:12/3/2007

lity of this novel compound as a new therapeutic option for patients affected by hypertension and related disorders such as diabetic nephropathy," stated Rene Belder, M.D., Pharmacopeia's Vice President of Clinical and Regulatory Affairs. "We look forward to the completion of our ongoing Phase 2a study in the first half of 2008 and hope to see the first clear demonstration of the compound's potential efficacy in hypertensive patients."

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically validated mechanisms of action in a single compound. There is considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Organon, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at h
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... new market research report is available ... Market for Hospital-Acquired Infection Control (Sterilization, ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... healthcare-associated infections (HAIs), demand has increased ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: The Impact of Healthcare ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html The ... is complex legislation that affects virtually every aspect ... are beginning to take effect now. IVD manufacturers ...
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... France, Key Trends and Opportunities to 2018 ... Synopsis The report provides in depth ... French personal accident and health insurance segment, ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
... - Biovest,International, Inc. (OTCBB: BVTI), a majority owned ... 2007 blinded interim data from the start of ... for Non-Hodgkin's,lymphoma (NHL) from September 2000 through June ... data that has been made available,to the Company ...
... at the 11th International Myeloma Workshop -, NORTH ... -- The International Myeloma Foundation (IMF) --,supporting research ... families, researchers and physicians -- today,said that updated ... Greece demonstrate improved survival for a wide,range of ...
Cached Medicine Technology:Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4
(Date:8/20/2014)... 2014 According to a new ... Diagnostics Market (Technologies: Very High, High, Medium, Low ... Diagnosis, Oncology, Autoimmune Diseases, Cardiac, Allergies and Others) ... and Forecast, 2013 - 2019", the global multiplexed ... in 2012 and is expected to grow at ...
(Date:8/20/2014)... New York, NY, August 20, 2014 Transrectal ultrasound ... cancer, but international reports have suggested that the number ... a new nationwide population-based study, Swedish researchers found that ... for a urinary tract infection within 30 days after ... hospital admissions over five years, reports The Journal ...
(Date:8/20/2014)... 2014 Ticket Down is a reliable ... FL at the Sun Life Stadium in early September. , ... when Brazil and Colombia meet at Sun Life Stadium in Miami ... teams in the world and will be a rematch of their ... will kick-off on Sept. 5 and will feature some of the ...
(Date:8/20/2014)... It’s no secret that millions of Americans ... Institute on Drug Abuse, nearly 24 million Americans are ... alarming is the fact that the total number of ... locked in a struggle with substance abuse often feel ... the newly-redesigned AbuseTreatmentCenters.net has released updated lists of ...
(Date:8/20/2014)... 20, 2014 A Missouri federal judge has ... who were treated with GranuFlo and NaturaLyte to the City ... of Baron and Budd. The judge rejected an assertion by ... they were invalid. (McGee, et al. v. Fresenius Medical Care ... Fresenius Medical Care, is the manufacturer of the dialysis products ...
Breaking Medicine News(10 mins):Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Severe infections with hospitalization after prostate biopsy rising in Sweden 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 3Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2
... WEST PALM BEACH, Fla., Aug. 25 For years, millions ... pantyhose to cover up unsightly varicose and spider veins. Now there,s ... Garden of Life,s ( www.gardeno f life.com ... clinical studies and millions of happy European women. , , ...
... ORLEANS, Aug. 25 Over 102,000 Americans are ... and a Slidell, Louisiana resident is making the most of his ... for the 2010 Transplant Olympics, twittering his progress, and furthering his ... a unique and personal level of hope and understanding by caring ...
... Study Suggests Division, Ambivalence and Hesitancy to Change; Demographics ... Aug. 25 Americans lack confidence that healthcare reform will deliver ... released today by the Thomson Reuters. , , ... a wide range of issues including the cost and quality of ...
... ... the aging eye , ... Francisco, CA (Vocus) August 25, 2009 -- EyeCare America, a national non-profit organization that provides ... a healthy aging eye in honor of September,s Save Your Sight Month., , , , ...
... ... of Honolulu are celebrating the fifth anniversary of their successful partnership by holding an ... ... healthcare education company, and Kapi,olani Community College of Honolulu are celebrating the fifth anniversary ...
... ... honest and forthright look at why Americans are overweight, overwhelmed, and confused, and ... ... (PRWEB) August 25, 2009 -- The question is not whether Americans are getting ...
Cached Medicine News:Health News:Garden of Life Launches Lovely Legs(TM) to Reduce Visible Signs of Varicose and Spider Veins 2Health News:Double Recipient Twitters Transplant Olympic Training and Tackles Nursing School 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 3Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 2Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 3Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 4Health News:Career Step and Kapi'olani Community College Celebrate Five Year Partnership 2Health News:The Naked Truth: Overweight, Overwhelmed and Confused 2
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... wavelength (532 nm and 940 nm) laser ... solution. This solid-state laser quickly and effectively ... vulgaris. VariLite offers the clinical versatility to ... deeper, larger vessels in a convenient, affordable ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: